Watanabe H, Nishio M, Miura M, Iijima T
Department of Pharmacology, Akita University School of Medicine, Japan.
J Mol Cell Cardiol. 1995 Jun;27(6):1271-9. doi: 10.1016/s0022-2828(05)82389-2.
Blocking of L-type Ca channels by highly hydrophilic dihydropyridines, NKY-722 and KV-1360, was investigated in single ventricular cells of guinea-pig hearts using the whole-cell voltage clamp technique. At a holding potential of -30 mV, NKY-722 (1-100 nM) decreased the amplitude of the L-type Ca channel current (ICa) in a concentration-dependent manner. NKY-722 did not change the time constants of the decay of ICa. In the presence of NKY-722 (1 microM), the steady-state inactivation curve was shifted toward a more negative potential (by -33.0 +/- 2.0 mV) without changing its slope factor. The use-dependent block was elicited at a pulse frequency of 3.3 Hz or more. Even after washing out the drug at -80 mV for 20 min, ICa inhibited by NKY-722 (100 nM) at -30 mV was scarcely recovered when the membrane potential was clamped back to -30 mV. A permanently charged compound KV-1360 (0.1-1 microM), a quaternary amine derivative of NKY-722, hardly affected ICa by intracellular and extracellular application. These results suggest that, in spite of the high degree of ionization (91% in the charged form at pH 7.4), the mode of the L-type Ca channel block by NKY-722 is quite similar to that by lipophilic dihydropyridines. Consequently, the neutral form of NKY-722 is the active compound and this reaches the dihydropyridine receptor by "membranous approach".
采用全细胞膜片钳技术,在豚鼠心脏单个心室细胞中研究了高亲水性二氢吡啶NKY - 722和KV - 1360对L型钙通道的阻断作用。在 - 30 mV的钳制电位下,NKY - 722(1 - 100 nM)以浓度依赖性方式降低L型钙通道电流(ICa)的幅度。NKY - 722没有改变ICa衰减的时间常数。在存在NKY - 722(1 μM)的情况下,稳态失活曲线向更负的电位移动(移动了 - 33.0±2.0 mV),而斜率因子不变。在3.3 Hz或更高的脉冲频率下可引发使用依赖性阻断。即使在 - 80 mV下洗脱药物20分钟后,当膜电位钳制回到 - 30 mV时,在 - 30 mV下被NKY - 722(100 nM)抑制的ICa几乎没有恢复。一种带永久电荷的化合物KV - 1360(0.1 - 1 μM),是NKY - 722的季胺衍生物,通过细胞内和细胞外应用几乎不影响ICa。这些结果表明,尽管NKY - 722的离子化程度很高(在pH 7.4时91%为带电形式),但其对L型钙通道的阻断模式与亲脂性二氢吡啶非常相似。因此,NKY - 722的中性形式是活性化合物,它通过“膜途径”到达二氢吡啶受体。